Seminars in thrombosis & hemostasis 2010: Impact factor and highest-cited articles from 2008 to 2009

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 8, 2011, Pages 863-867

  Favaloro, Emmanuel J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMETRY; HEMOSTASIS; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLICATION; REVIEW; THROMBOSIS;

BLOOD COAGULATION DISORDERS; HEMOSTASIS; HUMANS; JOURNAL IMPACT FACTOR; PERIODICALS AS TOPIC; THROMBOSIS;

EID: 84555204256     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1297364     Document Type: Review

References (60)

1. Schiff D, Burgess T. Editorial. Semin Thromb Hemost 2004 30 601-602
2. Favaloro E J. Editorial. Welcome to Seminars in Thrombosis and Hemostasis 2008! Semin Thromb Hemost 2008 34 1-2 (Pubitemid 351640876)
3. Schiff D. Eulogy. Eberhard Mammen, M.D. 19302008. Semin Thromb Hemost 2008 34 305
4. Favaloro E J. Editorial. Semin Thromb Hemost 2008 34 307
5. Favaloro E J. Editorial. Welcome to a special issue of Seminars in Thrombosis and Hemostasisthe closing issue for 2008. Semin Thromb Hemost 2008 34 693-696
6. Prasad A, Kwaan H C. In memoriam: a tribute to Eberhard F Mammen, M.D. (19302008). Semin Thromb Hemost 2008 34 693-696
7. Favaloro E J. A tribute to Eberhard F Mammen, M.D. (1930-2008). Semin Thromb Hemost 2008 34 8 703-707
8. Favaloro E J. Editorial. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009. Semin Thromb Hemost 2009 35 1-2 (Pubitemid 351640876)
9. Favaloro E J. Editorial. Farewell to 2010! Semin Thromb Hemost 2010 36 797-802
10. Favaloro E J. The journal impact factor: don't expect its demise any time soon. Clin Chem Lab Med 2009 47 11 1319-1324
11. Favaloro E J. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. Semin Thromb Hemost 2008 34 1 7-25 (Pubitemid 351640878)
12. Pierangeli S S., Chen P P., Raschi E et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008 34 3 236-250
13. Favaloro E J., Lippi G, Adcock D M. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis? Semin Thromb Hemost 2008 34 7 612-634
14. Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009 35 2 189-203
15. Favaloro E J. Clinical utility of the PFA-100. Semin Thromb Hemost 2008 34 8 709-733
16. Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009 35 3 313-324
17. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 2008 34 8 747-761
18. McGlasson D L., Fritsma G A. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 2009 35 2 168-180
19. Favaloro E J., Wong R C. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Hemost 2008 34 4 389-410
20. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008 34 1 39-57 (Pubitemid 351640881)
21. Fareed J, Hoppensteadt D A., Fareed D et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008 34 1 58-73 (Pubitemid 351640882)
22. Franchini M, Franchi M, Bergamini V, Salvagno G L., Montagnana M, Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost 2008 34 1 104-112 (Pubitemid 351640886)
23. Harrison P, Mumford A. Screening tests of platelet function: update on their appropriate uses for diagnostic testing. Semin Thromb Hemost 2009 35 2 150-157
24. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 2008 34 5 459-468
25. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009 35 2 158-167
26. Enjeti A K., Lincz L F., Seldon M. Microparticles in health and disease. Semin Thromb Hemost 2008 34 7 683-691
27. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009 35 5 515-524
28. Gouw S C., van den Berg H M. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009 35 8 723-734
29. Harenberg J. Development of new anticoagulants: present and future. Semin Thromb Hemost 2008 34 8 779-793
30. Lippi G, Favaloro E J. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 2008 34 7 604-611
31. Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009 35 4 400-406
32. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009 35 3 277-287
33. de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost 2009 35 4 356-366
34. Falanga A, Barbui T, Rickles F R. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 2008 34 2 204-210
35. Favaloro E J. Internal quality control and external quality assurance of platelet function tests. Semin Thromb Hemost 2009 35 2 139-149
36. Favaloro E J. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. Semin Thromb Hemost 2008 34 1 7-25 (Pubitemid 351640878)
37. Franchini M, Mannucci P M. Von Willebrand factor: another janus-faced hemostasis protein. Semin Thromb Hemost 2008 34 7 663-669
38. Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Semin Thromb Hemost 2009 35 8 760-768
39. Levi M, Schouten M, van der Poll T. Sepsis, coagulation, and antithrombin: old lessons and new insights. Semin Thromb Hemost 2008 34 8 742-746
40. Lippi G, Favaloro E J., Franchini M, Guidi G C. Milestones and perspectives in coagulation and hemostasis. Semin Thromb Hemost 2009 35 1 9-22
41. Pai M, Hayward C P. Diagnostic assessment of platelet disorders: what are the challenges to standardization? Semin Thromb Hemost 2009 35 2 131-138
42. Prechel M, Walenga J M. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2008 34 1 86-96 (Pubitemid 351640884)
43. Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 2008 34 2 147-153
44. Tincani A, Bazzani C, Zingarelli S, Lojacono A. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost 2008 34 3 267-273
45. Zwicker J I. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 2008 34 2 195-198
46. Berntorp E, Salvagno G L. Standardization and clinical utility of thrombin-generation assays. Semin Thromb Hemost 2008 34 7 670-682
47. Dempfle C E., Borggrefe M. Point of care coagulation tests in critically ill patients. Semin Thromb Hemost 2008 34 5 445-450
48. Favaloro E J., Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost 2009 35 8 794-805
49. Favaloro E J. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost 2008 34 1 113-127
50. Favaloro E J. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost 2009 35 1 60-75
51. Hunt B J. Pediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2008 34 3 274-281
52. Isbister G K. Procoagulant snake toxins: laboratory studies, diagnosis, and understanding snakebite coagulopathy. Semin Thromb Hemost 2009 35 1 93-103
53. Israels S J. Diagnostic evaluation of platelet function disorders in neonates and children: an update. Semin Thromb Hemost 2009 35 2 181-188
54. Kitchen S, Jennings I, Preston F E., Kitchen D P., Woods T A., Walker I D. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. Semin Thromb Hemost 2009 35 8 778-785
55. Levi M, Löwenberg E C. Thrombocytopenia in critically ill patients. Semin Thromb Hemost 2008 34 5 417-424
56. Lippi G, Maffulli N. Biological influence of physical exercise on hemostasis. Semin Thromb Hemost 2009 35 3 269-276
57. Nurden A T., Fiore M, Pillois X, Nurden P. Genetic testing in the diagnostic evaluation of inherited platelet disorders. Semin Thromb Hemost 2009 35 2 204-212
58. Palumbo J S. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost 2008 34 2 154-160
59. Prisco D, Grifoni E. The role of D-dimer testing in patients with suspected venous thromboembolism. Semin Thromb Hemost 2009 35 1 50-59
60. Favaloro E J. Editorial. 2011 Eberhard F. Mammen Award announcements. Semin Thromb Hemost 2011 37 431-439